

volunteer group, our data include challenge with 2 different sources of endotoxin. Although the response to each endotoxin source was not statistically different, there were decreased PMNs present in the CCRE versus Sigma groups, which, when both groups are combined, modestly increases the variability of this measure. Because of this increased variability and smaller sample size, we recognize that a larger sample size may have revealed a statistically significant correlation that we did not observe for the normal cohort. Second, the group with asthma had increased PMN responses relative to normal volunteers, but these differences were not statistically significant. Third, our study population was predominantly female, and it is possible that female sex may be important in asthma and response to pollutants. Finally, it is important to note that all of the patients with asthma studied in these protocols had mild intermittent disease and required no chronic controller medication. Nonetheless, within the asthma group (all of whom underwent challenge with the same source of endotoxin), we observed a significant correlation between endotoxin induced increases in airway inflammation and BMI.

To our knowledge, this is the first report examining a relationship between BMI and inflammatory response to inhaled endotoxin in asthma. Endotoxin has been linked to asthma severity in ambient air and domestic and occupational environments and is a good model for acute events associated with asthma exacerbation. There are a number of potential mechanisms by which BMI may be linked to the inflammatory response to inhaled endotoxin in asthma. We have reported that allergic airway inflammation may modify mCD14 expression in airway macrophages and monocytes, which may enhance their response to endotoxin. It is important to note, however, that without allergic and nonatopic controls with asthma, it is presently unclear whether atopy, asthma, or the combination of the 2 is responsible for the differences we observed between our study cohorts. Our group has also observed that even with modest changes in BMI, there is increased particle deposition in the airways. Thus, in patients with asthma, increased deposition of endotoxin related to body mass may allow an increased effective airway dose of endotoxin to interact with primed monocytes and macrophages. It is also possible that increased BMI reflects changes in inflammatory biology reported to occur in obesity, including increased leptin, which has recently been reported to promote eosinophil survival. Thus, obese patients with asthma may have modified response to endotoxin at a cellular level.

Regardless of the precise mechanism, it is important to consider the potential interaction between body mass and asthma exacerbation. Obesity likely represents an important target for intervention in many patients with moderate and severe asthma. Our data demonstrate that in asthma, further examination of both the effect of BMI on airway physiology relative to deposition of inhaled bioactive particles, as well as the effect of obesity on innate and acquired immune responses, is needed to understand the role of obesity in asthma pathogenesis and exacerbation.

Neil E. Alexis, PhD
David B. Peden, MD

From the Center for Environmental Medicine, Asthma and Lung Biology, Division of Pediatric Immunology and Infectious Diseases, Department of Pediatrics, 104 Mason Farm Road, CB#7310, University of North Carolina School of Medicine, Chapel Hill, NC 27516-7310.

Supported by National Institutes of Health grants RO1-HL62624, RO1-HL66559, GCRC grant RR-000046, and EPA CR829522.

Disclosure of potential conflict of interest: D. Peden has consultant arrangements with GlaxoSmithKline, Merck, and AstraZeneca, and has received grants from and is on the speakers bureau for GlaxoSmithKline. N. Alexis has declared that he has no conflict of interest.

REFERENCES

- Gilliland FD, Berhane K, Islam T, McConnell R, Gauderman WJ, Gilliland SS, et al. Obesity and the risk of newly diagnosed asthma in school-age children. *Am J Epidemiol* 2003;158:406-15.
- Shore SA, Fredberg JJ. Obesity, smooth muscle, and airway hyper-responsiveness. *J Allergy Clin Immunol* 2005;115:925-7.
- Weiss ST. Obesity: insight into the origins of asthma. *Nat Immunol* 2005;6:537-9.
- Rivera-Sanchez YM, Johnston RA, Schwartzman IN, Valone J, Silverman ES, Fredberg JJ, et al. Differential effects of ozone on airway and tissue mechanics in obese mice. *J Appl Physiol* 2004;96:2200-6.
- Bernstein JA, Alexis N, Barnes C, Bernstein IL, Bernstein JA, Nel A, et al. Health effects of air pollution. *J Allergy Clin Immunol* 2004;114:1116-23.
- Bennett WD, Zeman KL. Effect of body size on breathing pattern and fine particle deposition in children. *J Appl Physiol* 2004;97:821-6.
- Alexis N, Eldridge M, Reed W, Bromberg P, Peden DB. CD14-dependent airway neutrophil response to inhaled LPS: role of atopy. *J Allergy Clin Immunol* 2001;107:31-5.
- Boehlecke B, Hazucha M, Alexis N, Bromberg P, Peden DB. Low dose endotoxin enhances bronchial responsiveness to inhaled allergen in atopic asthmatics. *J Allergy Clin Immunol* 2003;112:1241-3.
- Alexis NE, Peden DB. Blunting airway eosinophilic inflammation results in a decreased airway neutrophil response to inhaled LPS in patients with atopic asthma: a role for CD14. *J Allergy Clin Immunol* 2001;108:577-80.
- Alexis NE, Lay JC, Almond M, Bromberg PA, Patel DD, Peden DB. Acute LPS inhalation in healthy volunteers induces dendritic cell maturation in vivo. *J Allergy Clin Immunol* 2005;115:345-50.

Available online February 7, 2006.
doi:10.1016/j.jaci.2005.12.1305

Dominance of human innate immune responses in primary *Francisella tularensis* live vaccine strain vaccination

To the Editor:

Francisella tularensis is the etiologic agent of the zoonotic disease, tularemia. An inoculum as small as 10 bacteria can cause a flulike disease with substantial morbidity and mortality among infected humans.^{1,2} Human tularemia presents in ulceroglandular, oculoglandular, oropharyngeal, pneumonic, and septic forms.^{1,3} Rapid administration of antibiotics prevents mortality in the majority of human cases if exposure doses are low and nonaerosol.²⁻⁴ Without early diagnosis and administration of antibiotics, high-dose aerosol exposure progresses rapidly to life-threatening pleuropneumonitis and systemic infection.³ The relative abundance of *F tularensis* in nature and the relative ease with which it may be administered raise concerns over its exploitation as a biothreat agent.^{1,3,4}

Report Documentation Page

Form Approved
OMB No. 0704-0188

Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.

1. REPORT DATE 1 MAY 2006	2. REPORT TYPE N/A	3. DATES COVERED -	
4. TITLE AND SUBTITLE Dominance of human innate immune responses in primary Francisella tularensis live vaccine strain vaccination. Journal of Allergy and Clinical Immunology 117:1187 - 1188		5a. CONTRACT NUMBER	
		5b. GRANT NUMBER	
		5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Fuller, CL Brittingham, KC Hepburn, MJ Martin, JW Petitt, PL Pittman, PR Bavari, S		5d. PROJECT NUMBER	
		5e. TASK NUMBER	
		5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) United States Army Medical Institute of Infectious Diseases, Fort Detrick, MD		8. PERFORMING ORGANIZATION REPORT NUMBER RPP-06-014	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)		10. SPONSOR/MONITOR'S ACRONYM(S)	
		11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited			
13. SUPPLEMENTARY NOTES The original document contains color images.			
14. ABSTRACT No abstract is available.			
15. SUBJECT TERMS Francisella tularensis, tularemia, live vaccine strain, LVS, natural killer cell, NK, T-cell receptor, TCR			
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT SAR
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified	
			18. NUMBER OF PAGES 3
			19a. NAME OF RESPONSIBLE PERSON

In the 1950s, an attenuated strain of *F tularensis* was developed into an Investigational New Drug status live vaccine (live vaccine strain [LVS]) administered by intradermal scarification.^{1,5,6} LVS vaccination has significantly lowered reports of laboratory-acquired tularemia, although the mechanism of protection (humoral or cell-mediated) is still unclear.^{1,3,7} Microagglutination assays performed at 28 days postvaccination (indicating anti-*F tularensis* IgG and IgM) are the clinical standard for gauging successful vaccination yet show poor correlation with specific, vigorous lymphocyte responses in LVS-vaccinated and naturally infected humans.⁸ Human anti-*F tularensis* immune serum resulting from vaccination with LVS is protective only against strains of reduced virulence, yet immunospecific and long-lasting cell-mediated immunity is the key to protection.^{5,7,9} Substantial data suggest that cell-mediated immunity may be more important than humoral immunity for providing long-lasting immunity against virulent strains of *F tularensis*.^{5,7,9} Therefore, we examined human immune responses to LVS vaccination to establish early cellular correlates of LVS-mediated protection predictive of successful vaccine outcomes.

Volunteers were recruited from US Army Medical Research Institute of Infectious Diseases (USAMRIID) personnel at risk of laboratory exposure to *F tularensis*. A minimal risk protocol to collect peripheral blood samples was approved by institutional review boards at the USAMRIID (Human Use Committee FY04-16). Donors provided informed consent and met eligibility criteria. Six healthy adults (4 males and 2 females, 22-54 years old) received a primary LVS vaccination and donated peripheral blood prevaccination and postvaccination. Mononuclear cells were purified by Ficoll gradients and assessed for changes in immune cell populations using flow cytometry and quadruple stained using directly conjugated mAbs (BD-Immunocytometry Systems and BD-Pharmingen, La Jolla, Calif). Cytometric bead array analysis was performed on serum samples (BD-Pharmingen). Analysis was performed using FlowJo (TreeStar, Inc, Ashland, Ore) and GraphPad Prism (GraphPad Prism Software, San Diego, Calif). All 6 subjects were immunologically naive before vaccination. All vaccinations had positive responses as indicated by initial formation of a small pustule/papule and subsequent ulceration.

Cell surface analysis of mononuclear cells revealed bias toward activation of innate versus acquired immune system components. The greatest changes in cellularity occurred on day +1 ($P < .001$ for day +1 versus all other days), a time frame consistent with innate immunity, but too short for unprimed acquired responses (Fig 1, A and B). When acquired immune system cells ($CD3^+$, $CD4^+$, $CD8^+$, T-cell receptor [TCR] $\alpha\beta^+$, $CD45RO^+$) were analyzed over all time points, only $CD4^+$ and $CD8^+$ cells were significantly changed at day +1 ($P < .05$ and $P < .01$, respectively).

Although $CD4^+$ and $CD8^+$ cells increased significantly on day +1 (Fig 1, A), these cells were not conventional TCR $\alpha\beta^+$ T cells, but rather TCR $\gamma\delta^+$ T cells ($CD8^+$ /





FIG 1. Cellularity changes in acquired and innate immune response to LVS vaccination. Peripheral blood was monitored for changes in acquired (A) and innate (B) immune cell surface markers over the course of several days prevaccination and postvaccination (as indicated). Symbols represent the mean percentage positive cells with $n = 6$.

$\gamma\delta TCR^+$), natural killer (NK) T cells ($CD56^+/CD8^+$), and monocytes ($CD4^+/CD14^+$) whose kinetics mirrored innate immune responses (Fig 1, B). When innate immune system components ($CD56^+$, $CD1a^+$, TCR $\gamma\delta^+$, human leukocyte antigen [HLA]-DR $^+$, $CD16^+$, $CD14^+$) were tracked over the course of the vaccination, NK cells, $\gamma\delta T$ cells, monocytes, granulocytes, and dendritic cells showed considerable changes in cellularity on day +1. Dramatic increases in $\gamma\delta T$ cells (Fig 2, A) and NK cells (Fig 2, B) were noted on day +1 ($P < .05$ and $P < .01$, respectively), with NK cells having the most prominent changes. LVS vaccination induced a strong proliferative signal for innate lymphocytes as measured by the upregulation of the IL-2 receptor high-affinity α chain, CD25 (Fig 2, C), whose induction is linked with progression into cell cycle.¹⁰ CD25 upregulation was highest on day +1 for all donors ($P < .01$) and was noted for NKT, $\gamma\delta T$, and NK cells. No similar correlations were seen between CD25 and TCR $\alpha\beta^+$ - $CD4^+$ or TCR $\alpha\beta^+$ - $CD8^+$ T cells, even at time points associated with primary acquired immune responses, days +8 to +14.

Our data strongly suggest that cellularity changes after human LVS vaccination strongly parallel innate immune system kinetics. These data are in accord with the murine LVS model in which mice deficient in T cells are still able to resist lethal LVS challenge for 3 to 4 weeks.⁵ This protection can be traced to proinflammatory cytokine production by innate immune components, chiefly NK and NKT cells.⁵ Although serum cytokine levels in our study were below the limit of detection (<20 pg/mL), the upregulation of the high-affinity IL-2 receptor chain (CD25) may indicate that a proinflammatory T_H1 -type response was



induced by LVS vaccination. All 6 of the subjects had positive anti-LVS titers by +28 days, yet there was as much as a 16-fold difference in positive microagglutination titers (Fig 2, D). Cellular responses at day +1 and +2 showed a much tighter cluster across all 6 subjects (less than 2-fold change between subjects), consistent with data suggesting the critical importance of cell-mediated immunity in long-term anti-*F tularensis* protection.^{5,7,9} Surprisingly, postvaccination titer bore no resemblance to the cellular immune response described (Fig 2, D). Combined with data suggesting cell-mediated responses are most critical to anti-*F tularensis* protective immunity, the question of the role of humoral immunity remains unanswered.^{5,7,9} Most importantly, our data point to cellular correlates of protection predictive of positive vaccine outcomes as early as 24 hours postinfection. Future studies to determine the gene-level responses to human LVS vaccination are underway in our laboratory.

We thank Dr G. Ruthel, K. Sellers-Meyers, M. T. Cooper, A. E. Kaczmarek, and N. A. Posten for scientific input and E. Torres-Melendez, R. Zamani, K. J. Hachey, and the USAMRIID Special Immunizations Program for excellent technical assistance. The opinions or assertions contained herein are those of the authors and are not to be construed as official policy or as reflecting the views of the Department of the Army or the Department of Defense.

Claudette L. Fuller, PhD*
Katherine C. Brittingham, PhD*
Matthew J. Hepburn, MD
James W. Martin, MD
Patricia L. Pettit, DO, MPH
Phillip R. Pittman, MD, MPH
Sina Bavari, PhD

*These authors contributed equally to this work.

From the United States Army Medical Research Institute of Infectious Diseases, Bacteriology Division, 425 Porter St, Frederick, MD 21702-5011. Dr Brittingham is the recipient of the National Research Council Fellowship. Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.

REFERENCES

- Isherwood KE, Titball RW, Davies DH, Felgner PL, Morrow WJ. Vaccination strategies for *Francisella tularensis*. *Adv Drug Deliv Rev* 2005;57:1403-14.
- Oyston PC, Quarry JE. Tularemia vaccine: past, present and future. *Antonie Van Leeuwenhoek* 2005;87:277-81.
- Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. Tularemia as a biological weapon: medical and public health management. *JAMA* 2001;285:2763-73.
- Burnett JC, Henchal EA, Schmaljohn AL, Bavari S. The evolving field of biodefense: therapeutic developments and diagnostics. *Nat Rev Drug Discov* 2005;4:281-96.
- Elkins KL, Cowley SC, Bosio CM. Innate and adaptive immune responses to an intracellular bacterium, *Francisella tularensis* live vaccine strain. *Microbes Infect* 2003;5:135-42.
- Titball RW, Oyston PC. A vaccine for tularaemia. *Expert Opin Biol Ther* 2003;3:645-53.
- Tarnvik A. Nature of protective immunity to *Francisella tularensis*. *Rev Infect Dis* 1989;11:440-51.
- Tarnvik A, Lofgren S. Stimulation of human lymphocytes by a vaccine strain of *Francisella tularensis*. *Infect Immun* 1975;12:951-7.
- Drabick JJ, Narayanan RB, Williams JC, Leduc JW, Nacy CA. Passive protection of mice against lethal *Francisella tularensis* (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine. *Am J Med Sci* 1994;308:83-7.
- Herzberg VL, Smith KA. T cell growth without serum. *J Immunol* 1987;139:998-1004.

Available online March 31, 2006.
doi:10.1016/j.jaci.2006.01.044